<DOC>
	<DOCNO>NCT03027843</DOCNO>
	<brief_summary>Assisted reproduction treatment patient low ovarian reserve big difficult clinical problem . Growth hormone ( GH ) crucial development follicle since preantral follicle ovulation promote steroid hormone gamete formation , increase granular cell sensitivity , inhibition follicular atresia . Latest research show GH improve egg quality regulate mitochondrial function oocytes increase rate embryo euploid . It become new argument promotion clinical pregnancy rate assist reproduction treatment . GH apply field assist reproduction 30 year experience applicable people , drug dosage , drug intervention time continue explore . 2015 China assist reproductive stimulate ovulation medicine expert consensus recommend joint GH poor ovarian response , repeat implantation failure patient old patient assisted fertility treatment , specific use time limit , daily dose drug curative effect . How maximize growth hormone potential advantage improve egg quality bother clinical doctor . We self-controlled retrospective analysis growth hormone application find average daily injection GH dose 2 iu 45 day significantly improve embryo quality patient low ovarian reaction . And long-acting recombinant human growth hormone available , make convenient patient . A forward-looking experimental expect answer clinical practical problem provide proper GH regimen low ovarian responder .</brief_summary>
	<brief_title>The Effect Growth Hormone Assisted Reproductive Technology Clinical Outcome Poor Responder</brief_title>
	<detailed_description>This study pilot study investigate effect growth hormone assist reproductive technology clinical outcome poor responder . Design : randomize controlled trial . Setting : Assisted reproductive technology unit . Patients : patient diagnose poor ovarian responder accordance inclusion criterion , meet exclusion criterion , repeat IVF treatment Mar 2017 Aug 2019 . Intervention : The comparison make GH group control group , group conduct mini-dose GnRH-a long protocol IVF treatment . GH group use Long-acting recombinant human growth hormone 14IU qw , day hCG . Main outcome measure : The primary outcome study live birth rate . The secondary outcome clinical pregnancy rate , number oocyte retrieve , fertility rate , normal fertilization rate , rate transferable embryo good quality embryo rate .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Women age ≥35 year ≤40 year . 2 . 2≤ AFC≤6 , AMH level ≥0.5 and≤ 1.1 ng/ml . 3 . Previous fail transfer cycle ≥2 4 . Did n't participate clinical subject three month . 5 . Written informed consent . 1 . Body mass index ( BMI ) ≥25 kg/m2 . 2 . Endocrine metabolic disease , diabetes , insulin resistance , hyperthyroidism , Cushing 's syndrome , hyperprolactinemia . 3 . Hypertension ( systolic blood pressure ≥140mmHg diastolic blood pressure≥90mmHg . 4 . Autoimmune diseases definitively diagnose , systemic lupus erythematosus , Sjogren 's syndrome , Hashimoto 's Thyroiditis , multiple sclerosis , rheumatoid arthritis , autoimmune hemolytic anemia , recurrent miscarriage . 5 . Ovarian neoplasm ≥4 cm diameter clear pathological diagnosis surgery . 6 . Complicated adenomyosis , endometriosis confirm surgery , ovarian endometriosis cyst ≥2 cm ultrasound , kind malignant tumor precancerous disease . 7 . Untreated hydrosalpinx . Eliminate fall Criteria : 1 . Withdraw drug take appropriate treatment measure serious adverse event happen trial , subject . 2 . Patients bad compliance . 3 . Subjects find breach inclusion criterion , accordance exclusion criterion test , exclude . 4 . Patients request withdrawal exit trial adverse event occur trial . 5 . No record treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>low ovarian reserve</keyword>
	<keyword>growth hormone</keyword>
	<keyword>embryo quality</keyword>
	<keyword>live birth</keyword>
	<keyword>clinical pregnancy</keyword>
</DOC>